ImmuRAID-LL2 antibody fragment labelled with technetium-99m data

At the European Association of Nuclear Medicine Congress in Lausanne, IMMU presented results of Phase I/II testing of its agent in the U.S. and Europe, showing accurate identification of at least one ...